前列腺癌表观遗传生物标志物与表观遗传靶向治疗的最新进展
该系统综述检索PubMed 2015年1月至2020年8月文献,初检1451篇,最终纳入62篇,并补充12篇基础研究,另讨论12项正在进行的表观遗传靶向治疗临床研究。表观遗传机制影响前列腺癌进展,理解特定表观遗传因子对改善治疗和调节耐药至关重要,临床前及临床研究为表观遗传治疗的临床部署提供路线图。
要点
- 表观遗传改变在前列腺癌进展中起关键作用,不依赖DNA序列改变。
- 临床前及已有临床研究提示靶向表观遗传因子的药物具有前景。
- 仍需更多工作确定该类药物能否加入前列腺癌现有治疗武器库。
核心结论
- 表观遗传机制影响前列腺癌进展,理解特定表观遗传因子对改善治疗和调节标准治疗耐药至关重要。
- 近期临床前研究及正在或已完成临床研究为表观遗传治疗临床部署提供路线图。
- 靶向表观遗传因子的药物具前景,但需更多工作确定其能否加入现有治疗武器库。
研究设计与样本
- 系统综述,检索PubMed 2015年1月至2020年8月文献,遵循PRISMA指南。
- 初检1451篇,最终纳入62篇,另纳入12篇该时间范围外的基础研究。
- 从clinicaltrials.gov检索靶向表观遗传因子的临床试验,并讨论12项正在进行的表观遗传靶向治疗临床研究。
主要发现
- 综述汇总了临床前和临床研究中表观遗传因素在前列腺癌中的作用。
- 表观遗传改变影响细胞行为并促进癌症发生或进展。
- 临床前研究及正在或已完成临床研究提示靶向表观遗传因子的药物具前景。
临床怎么用
- 理解特定表观遗传因子有助于确定如何改善前列腺癌治疗并调节标准治疗耐药。
- 临床前及正在或已完成临床研究为表观遗传治疗临床部署提供路线图。
局限性
- 检索限于2015年1月至2020年8月发表的文献。
- 需更多工作确定表观遗传靶向药物能否加入前列腺癌现有治疗武器库。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: In addition to genetic alterations, epigenetic alterations play a crucial role during prostate cancer progression. A better understanding of the epigenetic factors that promote prostate cancer progression may lead to the design of rational therapeutic strategies to target prostate cancer more effectively. OBJECTIVE: To systematically review recent literature on the role of epigenetic factors in prostate cancer and highlight key preclinical and translational data with epigenetic therapies. EVIDENCE ACQUISITION: We performed a systemic literature search in PubMed. At the request of the editors, we limited our search to articles published between January 2015 and August 2020 in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Clinical trials targeting epigenetic factors were retrieved from clinicaltrials.gov. EVIDENCE SYNTHESIS: We retrieved 1451 articles, and 62 were finally selected for review. Twelve additional foundational studies outside this time frame were also included. Findings from both preclinical and clinical studies were reviewed and summarized. We also discuss 12 ongoing clinical studies with epigenetic targeted therapies. CONCLUSIONS: Epigenetic mechanisms impact prostate cancer progression. Understanding the role of specific epigenetic factors is critical to determine how we may improve prostate cancer treatment and modulate resistance to standard therapies. Recent preclinical studies and ongoing or completed clinical studies with epigenetic therapies provide a useful roadmap for how to best deploy epigenetic therapies clinically to target prostate cancer. PATIENT SUMMARY: Epigenetics is a process by which gene expression is regulated without changes in the DNA sequence itself. Oftentimes, epigenetic changes influence cellular behavior and contribute to cancer development or progression. Understanding how epigenetic changes occur in prostate cancer is the first step toward therapeutic targeting in patients. Importantly, laboratory-based studies and recently completed and ongoing clinical trials suggest that drugs targeting epigenetic factors are promising. More work is necessary to determine whether this class of drugs will add to our existing treatment arsenal in prostate cancer.
引用
- Kumaraswamy A, Welker Leng KR, Westbrook TC, et al. Recent Advances in Epigenetic Biomarkers and Epigenetic Targeting in Prostate Cancer. Eur Urol. 2021. PMID: 33785255. doi:10.1016/j.eururo.2021.03.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。